Purpose: A randomized phase II trial of oral vs. intravenous (i.v.) vinorelbine was designed to determine the efficacy and safety of oral vinorelbine with an intrapatient dose escalation in previously untreated patients with advanced non-small-cell lung cancer (NSCLC).
Introduction
Lung cancer is the leading cause of cancer death in industrialized countries. Non-small-cell lung cancers (NSCLC) represent more than 80% of all lung cancers. The great majority of patients with NSCLC present with locoregionally advanced and unresectable (stage IIIB) or metastatic (stage IV) disease. Additionally, a large proportion of those undergoing surgery for cure will relapse and many of them will have distant metastases.
Vinorelbine (Navelbine®), a semi-synthetic vinca alkaloid, is now one of the major active drugs in NSCLC. Vinorelbine administered intravenously has been studied in several phase II trials. As a single agent, it has produced objective response rates of 8% to 37% and a median survival ranging from 33 to 40 weeks [1] . In phase III trials, single-agent vinorelbine showed consistent activity in terms of response rate and survival [2] [3] [4] . The drug toxicities were usually mild, with neutropenia being the dose-limiting toxicity [1] .
The intravenous (i.v.) administration of cytostatic agents is a considerable source of discomfort and stress to patients. This problem has been partly alleviated with the use of port-a-caths and peripheral access systemports. Nonetheless, these devices are expensive, painful in the short term and associated with complications (infections, bleeding and pneumothorax). Recently, several oral analogs of currently existing i.v. chemotherapeutic agents have been developed and are at present the subject of preclinical and early clinical trials. The convenience and cost-savings of avoiding visits to the chemotherapy units are additional advantages of oral agents [5] .
The initial oral formulations of vinorelbine included a powder-filled capsule and a first-generation soft-gelatin capsule. Clinical studies of this first soft-gelatin capsule showed the feasibility of oral administration of vinorelbine [6] . The activity of oral vinorelbine in NSCLC [7] and in advanced breast cancer (ABC) [8] seemed to be comparable to intravenous vinorelbine. However, these two initial oral formulations were abandoned because of manufacturing problems. Subsequently, a new soft-gelatin capsule formulation was developed and was shown to be stable for at least 24 months.
The clinical development of this new formulation of oral vinorelbine started in 1994 with a phase I dosefinding study in patients with ABC [9] . The maximum tolerated dose was 100 mg/m 2 weekly, and the recommended dose for further clinical investigations was 80 mg/m" weekly. Dose-limiting toxicities included neutropenia, nausea/vomiting and constipation due to autonomic neuropathy. Preliminary evidence of activity was demonstrated in first-and second-line patients with ABC; there were six objective responses out of 14 evaluable patients administered doses of 80 or 100 mg/m 2 /week. A comparative cross-over oral/i.v. bioavailability study showed that the bioavailability of the oral administration (soft-gelatin capsules, 80 mg/m 2 ) is 43 ± 14% of that with 25 mg/m 2 i.v. infusion [10] . Based on the linearity of vinorelbine pharmacokinetics with both routes of administration [9, 11] , it was established that the oral dose of 80 mg/m 2 corresponds to the intravenous dose of 30 mg/m", and the oral dose of 60 mg/m 2 is comparable to the intravenous dose of 25 mg/m 2 . At therapeutic doses, similar pharmacokinetic behavior and safety profiles were demonstrated for both routes. Interindividual variability in drug exposure was equivalent in both routes. Pharmacokinetics and pharmacodynamics were independent of the route of administration. Interestingly, the pharmacokinetic behavior of soft-gelatin capsules in fed and fasting conditions was found to be similar [12] .
An oral form of vinorelbine appears to be particularly attractive due to the ease of administration, provided its activity is similar to that of the i. v. preparation. Therefore, phase II studies of single-agent oral vinorelbine were conducted in NSCLC and ABC, the two major indications for the i. v. form. The initial phase II study of oral vinorelbine [13] in chemotherapy-naive NSCLC patients used a weekly dose of 80 mg/m 2 , i.e. the dose recommended in the phase I dose-finding study [9] . This trial was prematurely stopped because of excessive hematological toxicity [13] . In consequence, a multicenter study was initiated to investigate a new schedule of oral vinorelbine with an intrapatient dose escalation from 60 to 80 mg/nr/week. The activity of i.v. vinorelbine was assessed in a parallel group as an internal control to ensure consistency of patient selection and evaluation criteria. The principal objectives were to assess the efficacy and safety of oral vinorelbine in chemotherapy-naive NSCLC patients at a dose of 60 mg/m 2 /week for the first three administrations, and then increased to 80 mg/m 2 /week in the absence of severe neutropenia.
Patients and methods

Patients
Patients with histologically or cylologically confirmed locally advanced (stage 1MB) or metastatic (stage IV) NSCLC. who had not previously received chemotherapy were eligible for the study. Patients with brain metastases were ineligible Other eligibility criteria included the following: age between 18 and 75 years. Karnofsky performance status ^ 80. good bone marrow function (absolute neutrophils count > 2000/ml. platelet count > 100,000/ml and hemoglobin level > 11 g/dl). adequate hepatic and renal functions, including uspargine transaminase (AST), alanine transaminase (ALT) ^ 2.5 times the institutional upper limit of normal (1ULN), bilirubin < 1.5 times IULN. alkaline phosphatases $ 5 times IULN unless bone or liver metastases were present, serum creatinine < 1.5 times IULN, at least one bidimensionally measurable lesion (> 20 x 20 mm), no severe active infection at study entry, no severe uncontrolled comorbidity and no previous or concomitant malignancies. Previous radiotherapy was allowed provided it was completed at least four weeks prior to study entry and there were measurable lesions outside the radiation field. Concomitant radiotherapy was not allowed Written informed consent was obtained from all participating patients before study entry.
The pretrealmenl evaluation included medical history and physical examination, complete blood cell count, serum chemistries, liver function tests and appropriate staging studies to define the extent of metastatic disease (chest X-ray, chest CT-scan, abdominal ultrasound, thoracic and/or abdominal computed tomography, brain computed tomography and bone scan).
Treatment plan
Vinorelbine was administered on a weekly basis and continued until there was evidence of either disease progression, excessive toxicily or patient refusal. Oral vinorelbine was supplied as 30 mg or 40 nig softgelatin capsules. As at the beginning of the study there was a pending information on food interaction, all doses were taken with a glass of water either two hours before or two hours after a meal, without chewing or sucking the capsules Individual doses were rounded to the closest multiple of 10 mg by using a combination of 30 and 40 mg capsules. No primary prophylaxis with antiemetics was recommended. In case of nausea/vomiting, the first administration recommended was metoclopramide. If. despite metoclopramide. nausea/vomiting still occurred, a 5-HT 3 antagonist, such as ondansetron or granisetron, was recommended. I. v. vinorelbine was administered at a fixed dose of 30 mg/m 2 /week over five to ten minutes. The use of a central venous line was recommended for safe administration due to the local loxicity of vinorelbine Granulocyte colony-stimulating factors were allowed after the first course of treatment in patients with fever accompanying grade 3-4 neutropenia. or in case of asymptomatic grade 4 neutropenia lasting for at least five days. The use of erythropoietin was not recommended in the protocol
Drug schedule modifications
During treatment, patients had a weekly check of complete blood cell count, white blood cell (WBC) differential and platelet count. On the day of treatment the neutrophil count had to be > 1500/ul and platelets 5= 75.000/ul. In the oral vinorelbine arm dosing was adjusted according to the hematological tolerance of the first three administrations at 60 mg/m 2 /week If during this phase, no grade 4 neutropenia or no more than one episode of grade 3 neutropenia occurred, the dose was increased to 80 mg/m 2 in subsequent administrations, otherwise therapy was continued with 60 mg/m 2 . If during subsequent treatment at 80 mg/m 2 . grade 4 neutropenia or at least two consecutive episodes of grade 3 neutropenia occurred, the dose was reduced to 60 mg/m 2 . for the subsequent three administrations and then reincreased to 80 mg/m 2 Otherwise, the dose of oral vinorelbine remained unchanged, i.e. 80 mg/nr.
In case of peripheral neuropathy equal to or greater than grade 3, the administration of vinorelbine had to be held and a new examination had to be performed one week later. If the treatment could not be administered after a three-week interval because of hematological or neurologic toxicity, protocol therapy had to be discontinued. Serum electrolytes, total bihrubin. AST. ALT. alkaline phosphatase. glucose, lactic dehydrogenase (LDH), creatinine. calcium and total proteins were determined every four weeks
Study objectives
The primary study objective was to estimate the overall response rate of oral vinorelbine given at a dose of 60 mg/nr/week for the first three administrations and then at 80 mg/nr/week. The secondary objectives were to evaluate the response rate, the duration of response, the progression-free survival and the overall survival, as well as to evaluate treatment toxicity in both arms.
Assessment
Tumor measurements or evaluation were obtained at baseline, every eight weeks during treatment, and every three months thereafter, until disease progression. Tumor response definitions of measurable and evaluable disease were based on the WHO criteria [14] A complete response was defined as the disappearance of all lesions without the appearance of new lesions for at least four weeks. A partial response required at least 50% tumor reduction lasting for at least four weeks. The duration of response was calculated from the date of randomization to the date of first-documented progression. Progression-free survival was defined as the time from the date of randomization until progression or death due to any cause Survival was defined as the time from the registration date to the date of death or last contact.
The records of all patients who either responded or showed stable disease, were reviewed by an independent radiologist. Adverse events were recorded according to the Cancer and Leukemia Group B (CALGB) toxicity criteria.
Statistics
Sample size in the oral arm was determined by the one-sample multiple testing procedure for phase II clinical trials, as described by Fleming [15] .
To identify a response rate between 5% (minimum level of activity) and 15% (level of activity sufficient to justify stopping the recruitment) with a false positive error rate of less than 5% (oc < 0 05) and a false negative error rate of less than 15% (p 1 =g 0 15), an initial sample of 32 evaluable patients was required; if more than one and less than five patients in the initial cohort showed response, 32 further patients had to be included to obtain a final population of at least 64 fully evaluable patients in the oral arm.
In order to obtain information under the same experimental conditions with the i.v. vinorelbine treatment, this trial was designed with a concurrent reference group, and an unbalanced randomization (2 : 1) was retained. Therefore, the minimum number of subjects was estimated as 32 in the i.v vinorelbine arm and 64 in the oral vinorelbine arm. The study design did not allow for any formal statistical comparisons between both arms.
All the data were analyzed at a cut-off date of I May 2000.
Results
Patient characteristics
Between December 1997 and April 1999, 115 patients with advanced NSCLC were randomized; 77 to oral vinorelbine and 38 to i.v. vinorelbine. Of these, 114 patients were evaluable for safety (one patient assigned to oral vinorelbine was never treated) and 98 were eligible and evaluable for efficacy. In the oral arm, 13 patients were not evaluable for response, of whom seven were prematurely discontinued (less than four administrations) for reasons other than early progression, four were not eligible for reasons detailed further, one was never treated and one received four administrations but the radiological images were not available for the response review meeting. In the i.v. arm, four patients were not evaluable for efficacy of whom three were prematurely discontinued for reasons other than early progression, and one was not eligible, as further detailed. The last administration was performed in January 2000.
No patient was on treatment at the time of this analysis.
The reasons for ineligibility in the oral arm included grade 3 infection at study entry (one patient), cerebral metastasis at study entry (one patient), no bidimensionally measurable lesion (one patient), and stage IIA after external review (one patient). One patient in the i.v. arm was not eligible due to a small-cell-lung cancer histology. All patients who received study medication were included in the intent-to-treat analysis of response, progression-free survival and survival. These efficacy parameters were also analyzed in the 98 eligible and evaluable patients. The two treatment arms were wellbalanced for demographic and prognostic characteristics: 65% subjects in the oral arm and 55% in the i.v. arm had metastatic disease, 67% in the oral arm and 61% in the i.v. arm had at least two organs involved (Table 1) . In both arms the most common metastatic sites were lung, liver and bone. A high proportion of patients included in both arms (42% each) had tumor diameter larger than 50 mm.
Drug administration
A total of 954 administrations of oral vinorelbine and 396 administrations of i.v. vinorelbine were given ( Table 2 ). The median number of administrations was nine in the oral arm and ten in the i.v. arm. Twelve patients (16%>) in the oral arm and four patients (11%) in the i.v. arm received at least 20 administrations. Treatment delays occurred in 59% of patients and 14%> of administrations with oral vinorelbine, and in 71% of patients and 33% of administrations with i.v. vinorelbine. The principal reason for dose-delay was hematological toxicity. The mean dose-intensity was 62.5 mg/nr/week (89% of the planned dose) in the oral arm and 22.7 mg/nr/week (76% of the planned dose) in the i.v. arm. In the oral arm, 58 out of 68 patients (85%) after the third administration underwent a dose increase from 60 mg/m 2 /week to 80 mg/nr/week, as per protocol requirement. After dose escalation 13 patients (22%) subsequently had dose reduction from 80 to 60 mg/m 2 / week. Six patients then had a further dose reescalation from 60 to 80 mg/nr/week. A total of four patients had a central venous line. Abbreviations: CI -confidence interval; ITT -intent-to-treat.
CI): 6%-23%). The intent-to-treat response rate was 12% (9 of 77 patients; Table 3 ). In the oral arm, the median time to response was 8.7 weeks and the median duration of response was 7.7 months. Only one out of all partial responders in the oral arm was treated at the dose of 60 mg/m 2 /week throughout the study period, and all other patients received the majority of their administrations at the dose of 80 mg/m 2 /week, as per protocol. No responding patient in the oral arm had previously been treated with either surgery or radiotherapy. Five responders in the oral arm had metastatic disease at study entry. There were four responders out of 34 evaluable patients in the i.v. arm, for the overall response rate of 12% (95% CI: l%-23%); 11% in the intent-to-treat analysis. Two responders in the i.v. arm had metastatic disease. The time to response in the i.v. arm was 7.9 weeks and the median duration of response -5.5 months. Stable disease was documented in 40% and 37% of patients in the oral and i.v. arm, respectively. Disease progression was the only reason for treatment discontinuation in 62% of patients in the oral arm, and in 66% of patients in the i.v. arm.
The median progression-free survival in the oral and i.v. arm was 3.2 months and 2.1 months, respectively (Figure 1) . The median survival time was 9.3 months in the oral arm and 7.9 months in the i.v. arm (Figure 2) . The one-year-survival probability was 41% in the oral arm and 29% in the i.v. arm.
Toxicity
As expected, neutropenia was the most common hematological toxicity in both arms. Grade 3-4 neutropenia occurred in 46% of patients and in 7% of administrations in the oral arm, and in 62% of patients and 25% of administrations in the i.v. arm. In the oral arm, the incidence of grade 3-4 neutropenia (by patient) was dose-dependent: 11% (4% of cycles) for the first three administrations given at 60 mg/m 2 /week, 44% (8% of cycles) for the subsequent administrations of 80 mg/m 2 / week and 29% (7% of cycles) for the administrations which were dose-reduced from 80 to 60 mg/m 2 /week. No.
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No.
By patient
By administration
No. Febrile neutropenia and neutropenic infections were uncommon (Table 4) . Only 7% of patients in the oral arm and 5% in the i.v. arm received colony-stimulating growth factors. Grade 3 and 4 thrombocytopenia and anemia were relatively infrequent in both arms. The most common non-hematological toxicities in the oral arm were nausea, vomiting, diarrhea and anorexia. The incidence of severe side-effects, however, was relatively low. The incidence of grade 3-4 nausea and vomiting per patient increased according to the actual dose given: 49% and 30%, respectively at the dose of 60 mg/m 2 , and 76% and 56%, respectively at the dose of 80 mg/m . In the i.v. arm, nausea, anorexia, constipation and fatigue were the most frequent toxicities, but severe toxicities were also rare (Table 5) . Neurotoxicity in the oral arm included mild paresthesia and/or loss of deep tendon reflexes in 11% of patients, severe but reversible peripheral motor neuropathy in one patient, and ataxia that slowly resolved after drug discontinuation in one patient. In the i.v. arm, the most common neurotoxicity was constipation, which occurred in 24% of patients. One patient in the i.v. arm required a central venous line due to the occurrence of a thrombophlebitis.
Neutropenia
In the oral arm, there were three deaths possibly related to the study medication, as per investigator's assessment. The first death was caused by pulmonary hemorrhage, which occurred after 12 administrations, the last one given at 60 mg/m 2 . Its relationship to the study drug is questionable in view of the absence of any drop in platelet count or abnormality of coagulation tests. The second death was related to complications of a paralytic ileus in a 73-year-old patient after five administrations, of which the last was given at 80 mg/m 2 . The third patient died from pneumonia with septic shock in a context of neutropenia after six administrations, of which the last was given at 60 mg/m 2 . In the i.v. arm, one patient died from septicemia after two administrations.
Discussion
The goal of this study was to evaluate the activity and safety of oral vinorelbine in previously untreated patients with stage 11 IB or IV non-small-cell lung cancer. In both arms, the majority of patients presented with disseminated disease. Metastatic lesions were present in 65% of patients in the oral arm and in 55% of patients in the i.v. arm; 67% of patients in the oral arm and 61% in the i.v. arm had at least two organs involved, and 42% of patients in both arms had large tumors (^ 50 mm).
The dose-adjustment approach in the oral arm was aimed to optimize the hematological tolerance of the patient, while maintaining the efficacy reported for i.v. vinorelbine. A pharmacokinetic/pharmacodynamic relationship between hematological toxicity and drug exposure was reported in the phase I studies of oral vinorelbine [16] .
In this randomized trial, an overall response rate with oral vinorelbine was observed in 14% of the evaluable patients. In patients given oral vinorelbine the median progression-free survival and the median survival were 3.2 and 9.3 months, respectively. The relatively high proportion of patients with localised disease may have accounted in part for this favourable survival outcome. Nevertheless, these results suggest that oral vinorelbine is at least as effective as i.v. vinorelbine. No formal comparison with the i.v. arm was allowed due to the study design. However, both response rate and survival fall within the range of what has commonly been reported with single agent i.v. vinorelbine in randomized trials. For example, Depierre et al. [2] reported a response rate of 16% and a median survival of 8 months in 119 patients treated with i.v. vinorelbine, and Le Chevalier et al. [3] reported a response rate of 14% and a median survival time of 7.7 months in 208 patients. In these two trials, as opposed to the present study, stage 111 A. patients were also eligible. Crawford et al. [4] reported 12% response rate in 143 patients with stage IV disease and a median survival of 7.5 months. The response rate of 12% and a median survival of 7.9 months with i.v. vinorelbine in the present trial are also consistent with previous studies.
Neutropenia was the most frequent hematological toxicity in both study arms. In the oral arm, the incidence of grade 3-4 neutropenia per patient increased with the dose: from 11% (4% of cycles) at 60 mg/m 2 to 44% (8% of cycles) for the subsequent administrations given at 80 mg/m 2 /week. These findings are consistent with the results of a cross-over study that compared blood exposure to vinorelbine administered in oral and i.v. forms [10] . In that study a significant relationship for hematological toxicity was demonstrated between area under curve (AUQ asl ) and nadir of WBC, indicating that the higher occurrence of leucopenia is related to higher body exposure to vinorelbine. A similar relationship was found for both oral and i.v. routes.
Neutropenia required dose delay in about half of the patients and was associated with dose reduction in 29% of patients. Thus, similar to i.v. vinorelbine, close hematological monitoring is necessary for oral vinorelbine in order to adjust the dose to the hematological tolerance. Importantly, in both arms complicated neutropenia (febrile neutropenia and neutropenic infection) occurred only occasionally.
Oral administration was frequently accompanied by gastrointestinal toxicities; nausea and vomiting occurred in 83% and 65% of patients, respectively. Their incidence seemed to be correlated with the dose, however grade 3-4 events were infrequent (11% for nausea and 8% for vomiting). Importantly, only secondary emesis prophylaxis was recommended by the protocol. According to the predictable risk of acute emesis defined by Hesketh et al. [17] , the oral formulation of vinorelbine can be considered to be intermediate-risk drug for acute emesis. Therefore, for the well-being of patients, the use of antiemetics from the first intake of oral vinorelbine should be recommended. Dopamine antagonists could partially control nausea/vomiting, but 5-HT3 antagonists might be more effective.
In the oral arm, peripheral neuropathy and constipation were seen in only 11% of patients each. Ataxia was observed in one patient. This toxicity was reported earlier with the intravenous administration [18] .
Apart from the ease of administration, the advantage of an oral route is the elimination of injection-site reactions, which occur in around 10% of patients receiving i.v. vinorelbine [19] . The main reasons for preferring oral chemotherapy are, therefore, convenience and fewer problems related to i.v. access or needles. These advan-tages are relevant, provided that the efficacy and toxicity of the oral agent are comparable to those with the i.v. counterpart [5] . The results of this study show that the safety profile of oral vinorelbine is qualitatively comparable to that observed with i.v. vinorelbine, and the activity of both routes seems to be similar. Thus, oral vinorelbine can be considered a good alternative to i.v. formulation. These results justify the development of oral vinorelbine in combination with other major drugs used in NSCLC.
